

Jornada Informativa

Concursos do Programa de Trabalhos 2024



Global Health
EDCTP3



Cofinanciado pela
União Europeia

AICIB | AGÊNCIA DE
INVESTIGAÇÃO
CLÍNICA
E INOVAÇÃO
BIOMÉDICA

fct | Fundação
para a Ciência
e a Tecnologia

EDCTP3 – Global Health Partnership

 140M€



Global Health
EDCTP3

The Goal: enhance research capacity and accelerate the development of new or improved medical interventions for the identification, treatment and prevention of poverty-related infectious diseases, including emerging and re-emerging diseases in sub-Saharan Africa, through all phases of clinical trials, with emphasis on phase II and III trials.

HORIZON-JU-GH-EDCTP3-2024-01-01-two-stage: Developing novel, innovative HIV therapeutics for reducing the disease burden of HIV in sub-Saharan Africa

HORIZON-JU-GH-EDCTP3-2024-01-02-two-stage: Research on existing Malaria vaccines and development of new promising candidates

HORIZON-JU-GH-EDCTP3-2024-01-03-two-stage: Accelerating development and integration of therapeutics against Neglected Tropical Diseases (NTDs) in sub-Saharan Africa

HORIZON-JU-GH-EDCTP3-2024-01-04-two-stage: Tackling Antimicrobial Resistance (AMR) through R&D in novel and existing antimicrobials

HORIZON-JU-GH-EDCTP3-2024-01-05-two-stage: New tools, technologies and approaches for vector control in sub-Saharan Africa

HORIZON-JU-GH-EDCTP3-2024-01-06-two-stage: Innovative digital health solutions for sub-Saharan Africa

HORIZON-JU-GH-EDCTP3-2024-02-01-two-stage: Global Health EDCTP3 JU training fellowship with return phase

- **Two stage Calls: Opening 18 Jan 2024; Deadline First Stage: 4 April 2024**
- **Link:** <https://globalhealth-edctp3.eu/sites/default/files/2023-12/WP%202024%20Annex1A%20Call%20for%20proposals.pdf>

HORIZON-JU-GH-
EDCTP3-2024-01-01-
two-stage


Developing novel, innovative HIV therapeutics for reducing the disease burden of HIV in sub-Saharan Africa.

Scope - The proposals are expected to:

- Carry out advanced stage clinical trials of promising HIV therapeutic interventions, for example to broadly neutralising antibodies, long-acting antiretrovirals or gene therapy approaches.
- Proposals must carry out late-stage clinical research. Implementation research is not in scope for this topic.
- The research to be conducted must be inclusive and involve vulnerable groups, in particular infants, children and adolescents.
- Proposals should engage all relevant stakeholders
- Provide methodologies for translating research findings into public health practice and policy guidelines.

RIA
Two-stage
Total Budget: 22M€
≈ 5.5 M€/project
≈ 4 projects

Expected Outcomes



Evidence of efficacy, safety and clinical utility for health care professionals and clinicians in sub-Saharan Africa about **novel, targeted HIV therapeutics** that improve treatment outcomes and quality of life



Innovative HIV therapeutics that have demonstrated **meaningful advances over existing therapeutic interventions for patients living with HIV** in terms of their ability to improve efficacy, safety, adherence, **quality of life and reduce HIV-associated mortality and morbidity.**



Health Policy Makers and Public Health authorities have clinical data to create/improved clinical guidelines and best practices as well as design tailor-made HIV policies

Research on existing Malaria vaccines and development of new promising candidates

HORIZON-JU-GH-
EDCTP3-2024-01-02-
two-stage

Scope - The proposals are expected to:

- Advance knowledge on the **safety, efficacy and effectiveness** of **currently** recommended malaria vaccines or **new** malaria vaccines.
- Consider **Trials from Phase 2a**
- **Collection, analysis and sharing of pharmacovigilance data on vaccines that are currently registered or candidates in late-stage efficacy trials.**

RIA
Two-stage
Total Budget: 30 M€
≈ 15M€/project
≈ 2 projects

Expected Outcomes



Generating **evidence required for accelerating registration of new vaccine candidates**
Generating long-term **safety and efficacy data on currently registered vaccines**



Generating **evidence-based recommendations on how to boost manufacturing capacity** and build an efficient supply chain for vaccines in general, and malaria vaccines in particular sub-Saharan Africa.

Safety and efficacy results from other vaccines, especially those targeting all stages of plasmodium falciparum lifecycle.

Accelerating development and integration of therapeutics against Neglected Tropical Diseases (NTDs) in sub-Saharan Africa

HORIZON-JU-GH-
EDCTP3-2024-01-03-
two-stage

Scope - The proposals are expected to:

- Conduct **clinical trials on therapeutics for NTDs** in the scope of the Global Health (list in the topic)
 - Conduct **clinical trials of combination already existing**
 - Re-purposing or clinical trials on new interventions for infections where therapeutics are lacking entirely
- **Implementation research** of pharmaceutical interventions for several NTDs
- The research to be conducted must involve vulnerable groups and all stakeholders

RIA
Two-stage
Total Budget: 22 M€
≈ 5 M€/project
≈ 4 projects

Expected Outcomes




Accelerate development of therapeutics towards control and elimination of NTD



Improve the understanding of barriers for progression of existing and new therapeutics against NTDs through the R&D pipeline.



Generate evidence-based recommendations on how to better integrate research and innovation in efficient supply chains for NTDs



Gain a better understanding of country health needs, to ensure a better management of patients with NTDs

Tackling Antimicrobial Resistance (AMR) through R&D in novel and existing antimicrobials

HORIZON-JU-GH-
EDCTP3-2024-01-04-
two-stage

RIA
Two-stage
Total Budget: 24 M€
≈ 6 M€/project
≈ 4 projects

Scope - The proposals are expected to:

- Conduct R&D on the better use of existing antimicrobials to reduce AMR
- **Conduct late-stage clinical R&D on novel antimicrobials** with improved properties (efficacy, safety, resistance pattern, useability) for infections
- Develop innovative **antimicrobial stewardship strategies** in human health on how to tackle **AMR based on the One Health approach**
- **Develop and implement cost effective, acceptable and feasible infection prevention and control (IPC) strategies**, in reducing AMR in healthcare facilities and communities.
- **Only proposals focusing their research on existing and/or novel antimicrobials from phase 3 onwards will be eligible**
- **Assess the impact, contribution, utility, accessibility, equity and cost-effectiveness of proposed interventions on AMR** across socioeconomic settings in Sub-Saharan Africa

Expected Outcomes



Improvement of the use of existing antimicrobials to reduce AMR and providing data contributing to their equitable access in sub-Saharan Africa



Advancement of late-stage clinical R&D of novel antimicrobials with improved properties (efficacy, safety, resistance pattern, useability) in the clinical trials pipeline



Data about development and implementation of antimicrobial stewardship (AMS) processes to optimise the use of antimicrobial medicines in human health and reduce antimicrobial resistance (AMR), employing the One Health approach;

New tools, technologies and approaches for vector control in sub-Saharan Africa

HORIZON-JU-GH-
EDCTP3-2024-01-05-
two-stage

RIA

Two-stage

Total Budget: 18.4 M€

≈ 6.1 M€/project

≈ 3 projects

Scope - The proposals are expected to:

- Proposals may consider **new surveillance tools, vector traps, insecticide, genetic manipulation, sterilization agents, etc...**
- **Eligible Diseases:** *Chikungunya, Dengue, Lymphatic filariasis, Rift Valley fever, Yellow Fever, Schistosomiasis, Onchocerciasis, Plague, Leishmaniasis, Crimean-Congo haemorrhagic fever, Sleeping sickness and malaria.*

Expected Outcomes



Development and evaluation of tools, technologies and approaches for vector-borne diseases, including vector control and disease management technologies.

Innovative digital health solutions for sub-Saharan Africa

HORIZON-JU-GH-
EDCTP3-
2024-01-06-two-stage

RIA
Two-stage
Total Budget: 20 M€
≈ 5 M€/project
≈ 4 projects

Scope - The proposals are expected to:

- Target demonstrated highest medical needs in Sub-Saharan Africa and justified context-specific needs;
- Develop, improve or upscale solutions, with early-stage involvement of end users and health services implicated;
- Propose solutions which demonstrate seamless integration interoperability with key existing national, regional or global systems
- Propose tools which are sustainable, accessible, open-source, evidence based and which follow the standards of data protection and digital health global public goods
- Be based under the scope of Global Health EDCTP3 and national/regional digital health strategies

Expected Outcomes



Development, improvement and/or scaling-up of digital **innovative solutions supporting clinical research** through smart, highly innovative digital health technologies or concepts to **accelerate the development of preventive, therapeutic or diagnostic interventions** addressing poverty-related diseases in sub-Saharan Africa



Development, improvement and or Scale-up of digital technologies in public health interventions that can serve as drivers for the **strengthening of health systems in sub-Saharan Africa**



Contribution to **the implementation of national and/or overarching regional digital health strategies**, in accordance to AU-EU Innovation Agenda.



HORIZON-JU-GH-
EDCTP3-2024-
02-01-two-stage

CSA

Two-stage

Total Budget: 3.5 M€

≈ 3.5 M€/project

≈ 1 project

Max to third party:

300 000€

Global Health EDCTP3 JU training fellowship with return phase

Scope - The proposals are expected to:

- **Implement a master's level training programme** in a discipline relevant for the Global Health EDCTP3 JU, providing transferable R&D skills, fostering innovation and entrepreneurship, incl. commercialisation of results, Intellectual Property Rights, communication, public engagement, and citizen science.
- The training provided by the academic institutions is expected to be **complemented by training modules provided by pharmaceutical companies.** (pharmaceutical companies will join the consortium as beneficiaries and/or associated partners at a later stage.)
- An open, fair and transparent procedure for selecting the fellows coming from different geographical regions of SSA, based on quality and with appropriate gender balance;
- The training for **each fellow should include a first phase** (or outgoing phase) between 12-24 months **enrolment into an academic organization, and a second phase** (or return phase) of at least 12 months **in the country of origin of the fellow;**
- **A robust training and mentorship mechanisms** to support the fellows through their first training phase and second home return phase;

Expected Outcomes



Master's level training programme in a discipline relevant for the Global Health EDCTP3 JU, providing transferable R&D skills, fostering innovation and entrepreneurship, incl. commercialisation of results, Intellectual Property Rights, communication, public engagement, and citizen science.

EDCTP3 – Global Health Partnership

**Opening of the
Call
18 January 2024**


**First Stage
Submission
4 April 2024**

**First Stage
Results
July 2024**

**Second Stage
Submission
Mid September
2024**

**Final Results
December 2024**

Cluster Health - National Contact Point Team



Anabela Isidro

**Member of the Board
Delegate and National Contact Point for
Health in Horizon Europe**

✉ Anabela.isidro@aicib.pt
☎ + 351 910 700 176



Isabel Carvalho-Oliveira

**Delegate and National Contact Point for
Health in Horizon Europe**

✉ Isabel.oliveira@aicib.pt
☎ + 351 910 502 378

**For more information register
in AICIB database**



<https://forms.office.com/Pages/ResponsePage.aspx?id=ac2JWErcU0K3wEWBV5k92gEbQWoj2iNLILj3TbCLQvBUMVZIQTAYWVA1N0IyWENVMEhSTjk0NTE0NS4u>